Back to Journals » Infection and Drug Resistance » Volume 8

Efinaconazole in the treatment of onychomycosis

Authors Lipner S, Scher R

Received 5 March 2015

Accepted for publication 13 April 2015

Published 1 June 2015 Volume 2015:8 Pages 163—172

DOI https://doi.org/10.2147/IDR.S69596

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Professor Suresh Antony

Shari R Lipner, Richard K Scher

Department of Dermatology, Weill Cornell Medical College, New York, NY, USA

Abstract: Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mechanism of action, in vitro and in vivo data, clinical trials, safety, and quality-of-life data of efinaconazole as it applies to the treatment of onychomycosis.

Keywords: efinaconazole, Jublia, onychomycosis, fungal infection, nail infection
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]